Cervical Carcinoma in Shatby University Hospital and Its Relation to Human Papilloma Virus

incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer

Completed

Looking for future studies?

Key information

Conditions

Cervical Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Sex eligibility

Female

Study type

Observational

Primary location

Hossam Hassan El Sokkary

Alexandria, Egypt

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

cervical cancer

Exclusion criteria

none

Treatment and study plan

human papilloma virus testing and genotyping in cervical cancer cases

Diagnostic Test

an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.

Primary outcomes

Detection of human papilloma virus infections and genotyping using real time PCR

Time frame: 10 days

Sponsors and collaborators

Lead sponsor

Hossam Hassan Aly Hassan El Sokkary

Other

Registry information

Important dates

Study start: 2019
Primary completion: 2022
Study completion: 2022
First posted: Sep 14, 2022
Registry last updated: Oct 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed